LG Chem will jointly sell Nesp & Regpara with Kyowa Kirin

Treatment for chronic kidney disease patients with total annual sales of 27 billion won

LG Chem is in charge of clinic-level sales and Kyowa Kirin Korea is in charge of general hospital-level sales

LG Chem announced on the 28th that it has signed a contract with Kyowa Kirin Korea to jointly sell two drugs, Nesp(Darbepoetin Alfa) and Regpara (Cinacalcet Hydrochloride)' in Korea.

 

LG Chem is in charge of sales at the clinics level, and Kyowa Kirin Korea is in charge of sales at the general hospital level.

 

Nesp is a continuous hematopoietic agent used to treat anemia in patients with chronic kidney disease.

 

It is prescribed for hemodialysis or peritoneal dialysis patients or patients with chronic kidney disease before dialysis.

 

LG Chem explains that treatment is highly convenient because it only needs to be administered once every one to two weeks.

 

Since its release in South Korea in 2010, it has been steadily generating more than 20 billion won in sales.

 

According to IQVIA, a pharmaceutical market research firm, Nesf's sales last year were 21.1 billion won.

 

Regpara is a treatment for secondary parathyroidism in patients with chronic kidney disease.

 

It can be treated with oral administration once a day.

 

Secondary parathyroidism is a disease in which excessive production of parathyroid hormones continues due to decreased renal function and the size of parathyroid glands increases, and is known to be a progressive disease that intensifies as chronic kidney disease progresses.

 

Regpara's revenue last year was 6.2 billion won.

 

With the joint sales of Nesp and Legpara, LG Chem can expect about 27 billion won.

 

LG Chem explained that the two drugs have the largest market share among drugs of the same family.

 

Synergy with existing products is also expected.

 

LG Chem has Espogen, the first-generation hematopoietic agent, and Nestykal, a treatment for hyperkalemia.

 

Through this joint sale, the company plans to present expanded treatment options to medical staff with kidney disease.

 

An official from LG Chem said, "We will continue to present various treatment options with customer value as the top priority.

 

We will do our best to expand the market as soon as possible based on our strong national sales network and long business experience in the area of kidney disease." An official from Kyowa Kirin Korea said, "We expect that the joint sales partnership between Kyowa Kirin Korea and LG Chem will further increase the awareness of Nesp and Regpara to hospitals, clinics, and small and medium-sized hospitals.

 

The two companies will make efforts to deliver higher levels of information and supply stable products to medical staff."